Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment

Percentage of patients who reach target fasting plasma glucose (90-130 mg/dL)

Time frame: At Weeks 12 and 24

Percentage of patients with HbA1c <7%, <7.5%, and <8%

Time frame: At Week 24

Mean change from baseline in HbA1c across HbA1c subgroups category (≤8%, >8 to 9%, and >9%)

Time frame: Baseline to Week 12 and Week 24

Mean change from baseline in fasting plasma glucose

Time frame: Baseline to Week 12 and Week 24

Assessment of patient reported outcomes (satisfaction on treatment and perception of hypoglycemia/hyperglycemia) based on the Diabetes Treatment Satisfaction Questionnaire (DTSQ)

Time frame: Baseline to Week 24

Change in Diabetes Treatment Satisfaction Questionnaire score

Time frame: Week 24

Number of hypoglycemic events

Time frame: From inclusion up to Week 24

Number of adverse events

Time frame: From inclusion up to Week 24